Acura Pharmaceuticals, Inc. (ACUR) Announces Quarterly Earnings Results, Misses Estimates By $0.07 EPS
Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) announced its quarterly earnings data on Monday. The specialty pharmaceutical company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by $0.07, Bloomberg Earnings reports. Acura Pharmaceuticals had a net margin of 14.91% and a return on equity of 112.19%. The business had revenue of $0.09 million during the quarter.
Acura Pharmaceuticals (ACUR) opened at 0.4695 on Tuesday. The firm’s market capitalization is $5.58 million. Acura Pharmaceuticals has a one year low of $0.40 and a one year high of $1.87. The company has a 50-day moving average of $0.51 and a 200 day moving average of $0.57.
Acura Pharmaceuticals Company Profile
Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.
Receive News & Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.